Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,322 papers from all fields of science
Search
Sign In
Create Free Account
PI3K-delta Inhibitor TGR-1202
Known as:
TGR-1202
An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
NCIt Antineoplastic Agent Terminology
Narrower (1)
RP5264
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
M. Davids
,
I. Flinn
,
+28 authors
S. O'brien
2017
Corpus ID: 132156109
Matthew S. Davids, MD1, Ian W. Flinn, MD, PhD2,3, Anthony R. Mato, MD4, Owen A. O'Connor, M.D., Ph.D.5, Danielle M. Brander, MD6…
Expand
2017
2017
UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR‐1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL
M. Davids
,
H. Kim
,
+14 authors
J.R. Brown
2017
Corpus ID: 80109690
2016
2016
Long-term follow-up of the PI3K{delta} inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and…
H. Burris
,
I. Flinn
,
+17 authors
O. O’Connor
2016
Corpus ID: 79261844
7512Background: TGR-1202 is a novel, once-daily PI3Kδ inhibitor with a differentiated safety profile from other PI3Kδ inhibitors…
Expand
2016
2016
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study
M. Davids
,
Haesook T. Kim
,
+13 authors
Jennifer R. Brown
2016
Corpus ID: 79374728
Introduction The oral BTK inhibitor ibrutinib is highly effective at inducing partial responses (PR) in relapsed or refractory (R…
Expand
2015
2015
TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma
O. O’Connor
,
I. Flinn
,
+10 authors
H. Burris
2015
Corpus ID: 78859641
Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor which exhibits a differentiated safety profile from other PI3K…
Expand
2015
2015
A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia
D. Mahadevan
,
E. Pauli
,
+4 authors
M. Schreeder
2015
Corpus ID: 77905609
Introduction: TGR-1202 is a next generation, once daily, oral PI3Kδ inhibitor that displays promising clinical activity in…
Expand
2015
2015
Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
M. Lunning
,
J. Vose
,
+16 authors
S. O'brien
2015
Corpus ID: 57310257
Introduction: Ublituximab (UTX) is a novel anti-CD20 mAb that has been glycoengineered for enhanced ADCC. TGR-1202 is a novel…
Expand
2014
2014
Activity of TGR-1202, a novel once-daily PI3K{delta} inhibitor, in patients with relapsed or refractory hematologic malignancies.
H. Burris
,
M. Patel
,
+10 authors
I. Flinn
2014
Corpus ID: 81151423
2513 Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor. Preliminary data from an ongoing Ph I study of TGR-1202…
Expand
2014
2014
TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma
H. Burris
,
M. Patel
,
+10 authors
I. Flinn
2014
Corpus ID: 79362321
Background: TGR-1202 is a novel oral, next generation PI3Kδ inhibitor which notably lacks the hepatotoxicity associated with…
Expand
2013
2013
The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells
C. Deng
,
Christine M. McIntosh
,
+6 authors
O. O’Connor
2013
Corpus ID: 78859337
Background The constitutively activated PI3K/AKT/mTOR pathway plays a key role in the proliferation and survival of cancer cells…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE